Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials.

ABSTRACT:

Background

Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases.

Purpose

Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relation

SUBMITTER: Hinnen D 

PROVIDER: S-EPMC6452802 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature